Hematology

Clinical pharmacy services in hematology can have a significant impact, and the Pharmacy Times® Hematology resource center provides clinical news and articles about the topic. Here, visitors will find information about upcoming hematology conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?
[[thumbnail_alt_text]]
The study evaluated lymphoma characteristics and outcomes in hepatitis C virus-associated B-cell non-Hodgkin lymphoma in African American patients.
 
[[thumbnail_alt_text]]
A novel, off-the-shelf bispecific antibody could serve as a new treatment option for patients with non-Hodgkin lymphoma who don’t respond to CAR T-cell therapy.  
 
[[thumbnail_alt_text]]
A study looked at adherence rates and potential predictors of nonadherence in patients with hemophilia receiving emicizumab.
 
[[thumbnail_alt_text]]
A prospective analysis of the CLL14 trial showed that fixed-duration treatment of venetoclax plus obinutuzumab achieved high rates of undetectable minimal residual disease.
 
[[thumbnail_alt_text]]
Patients receiving novel oral therapeutics often have a high dependence on financial assistance; specialty pharmacies may help facilitate access to these therapies.
 
[[thumbnail_alt_text]]
Pharmacy Times® will be on site at the 61st American Society of Hematology Annual Meeting and Exposition.
 
[[thumbnail_alt_text]]
Researchers showed that treating multiple myeloma cells with gamma-secretase inhibitors allowed CAR T-cells to more accurately treat cancer tumors.
 
[[thumbnail_alt_text]]
Top news of the day from across the health care landscape.
 
[[thumbnail_alt_text]]
The FDA granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) for the treatment of mantle cell lymphoma in adults who have received at least 1 prior therapy.
 
[[thumbnail_alt_text]]
With vincristine in short supply, Teva will resume production of the chemotherapy agent following its previous decision to remove the product from the market. 
 
[[thumbnail_alt_text]]
Survivors of long-term diffuse large B-cell lymphoma found to have a higher risk of developing a second primary cancer.
[[thumbnail_alt_text]]
A study looked at the incidence of thrombosis in patients being treated with ibrutinib for hematologic malignancies.